Target intelligence / Profile preview

Low-density lipoprotein oxidation process

Molecular classification
Other
01

Overview

The **low-density lipoprotein oxidation process** refers to the oxidative modification of low-density lipoprotein (LDL) particles, primarily by reactive oxygen species (ROS) and various cellular enzymes within the vascular wall. This process is characterized by initial oxidation of the polyunsaturated fatty acids in the phospholipid component of LDL, followed by further oxidation of cholesterol esters, unesterified cholesterol, and the protein component apolipoprotein B100[1][7][10]. As LDL becomes oxidized (producing oxLDL), it is more avidly taken up by macrophage scavenger receptors (such as CD36 and SR-A), leading to the formation of lipid-laden foam cells—a hallmark of early atherosclerotic lesions[7][8]. Oxidized LDL also contributes to endothelial dysfunction, monocyte chemotaxis, smooth muscle cell proliferation, and plaque instability[7][9]. The process can be induced by cellular oxidants (e.g., hydrogen peroxide, superoxide, hypochlorous acid), transition metals, and oxidizing enzymes (such as myeloperoxidase, lipoxygenase, and hemoglobin-derived iron)[2][4][5][6]. The local oxidation of LDL within the arterial wall and even within lysosomes of macrophages is implicated as a key step in the pathogenesis of atherosclerosis[8][9]. Although lowering LDL oxidation is a key therapeutic goal in cardiovascular disease, the "oxidation process" itself is not a drug target but a pathophysiological mechanism[7]. **Note:** - This entry describes a *biological process*, not a discrete molecular entity or canonical drug target. There is nothing to abbreviate, it is not a receptor, enzyme, transporter, or similar target, and therefore “is_target: false” and “is_incorrect: true” as per your guidelines. - Drugs such as antioxidants and statins may have indirect effects on LDL oxidation, but no approved drugs act specifically on the oxidation process as a molecular target. - “Oxidized LDL” (oxLDL) is often measured as a biomarker in cardiovascular disease research[3][7].

Other names
LDL oxidationLDL particle oxidationOxidation of low-density lipoprotein
02

Biological functions

Lipid peroxidationOxidative modification of lipoproteinsInitiation of foam cell formation
03

Disease associations

Cardiovascular diseaseAtherosclerosisInflammation
04

Biomarkers

Oxidized LDL (oxLDL)Malondialdehyde-modified LDL (MDA-LDL)4-hydroxynonenal (HNE)-modified LDL

Beyond the preview

Go deeper on Low-density lipoprotein oxidation process.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Low-density lipoprotein oxidation process.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call